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Objective: Thirty years ago it was demonstrated that folic acid taken before
pregnancy and in early pregnancy reduced the risk of a neural tube defect (NTD).
Despite Public Health Initiatives across Europe recommending that women take
0.4mg folic acid before becoming pregnant and during the first trimester, the
prevalence of NTD pregnancies has not materially decreased in the EU since 1998,
in contrast to the dramatic fall observed in the USA. This study aimed to estimate
the number of NTD pregnancies that would have been prevented if flour had
been fortified with folic acid in Europe from 1998 as it had been in the USA.
Morris et al. Prevention of NTDs in Europe
Design and Setting: The number of NTD pregnancies from 1998 to 2017 that would
have been prevented if folic acid fortification had been implemented in the 28 countries
who were members of the European Union in 2019 was predicted was predicted using
data on NTD prevalence from 35 EUROCAT congenital anomaly registries and literature
searches for population serum folate levels and folic acid supplementation.
Results: From 1998 to 2017 an estimated 95,213 NTD pregnancies occurred amongst
104 million births in the 28 countries in the EU, a prevalence of 0.92 per 1,000 births.
The median serum folate level in Europe over this time period was estimated to be 14.1
µg/L. There is a lack of information about women taking folic acid supplements before
becoming pregnant and during the first trimester of pregnancy, with one meta-analysis
indicating that around 25% of women did so. An estimated 14,600 NTD pregnancies
may have been prevented if the European countries had implemented fortification at the
level adopted by the USA in 1998 and 25% of women took folic acid supplements. An
estimated 19,500 NTD pregnancies would have been prevented if no women took folic
acid supplements.
Conclusions: This study suggests that failure to implement mandatory folic acid
fortification in the 28 European countries has caused, and continues to cause, neural
tube defects to occur in almost 1,000 pregnancies every year.
Keywords: neural tube defects, prevention, folic acid, fortification, Europe
INTRODUCTION
Thirty years ago (in 1991) the Medical Research Council Vitamin
Study randomized controlled trial showed that taking 4mg folic
acid before conception reduced the risk of a pregnancy with
spina bifida, anencephaly or encephalocele (neural tube defects)
by an estimated 72% (1). Dietary modification alone is not likely
to achieve a high enough daily intake of folate to provide a
reasonable reduction in risk; taking folic acid supplements or
eating food fortified with folic acid is necessary.
Mandatory fortification of flour with folic acid has been
introduced in 78 countries starting with the United States of
America (USA) in 1998, over 20 years ago (2, 3). Despite evidence
that such fortification is effective (2, 4–10), mandatory folic acid
fortification of flour has not been introduced in Europe. Women
in Europe are currently advised to take 0.4mg folic acid (in the
form of tablets or capsules) before pregnancy and in the first
trimester to reduce their risk of a neural tube defect (NTD)
pregnancy (11).The prevalence of NTDs has not decreased in
Europe, with an estimated prevalence of 0.91 per 1,000 births
from 1991 to 2011 (12) in comparison to the prevalence in
Canada where the prevalence of NTDs decreased from 1.58 per
1,000 births before fortification to 0.86 per 1,000 births after
fortification (6) and in the USA where the prevalence of spina
bifida and anencephaly reduced from 0.76 per 1,000 births pre-
fortification to 0.56 per 1,000 births after fortification (4).
Daly et al. demonstrated that there is a log linear association
between a woman’s serum folate level and her risk of having
an NTD pregnancy (13). A meta-analysis by Wald et al.
subsequently estimated that serum folate concentrations increase
by 0.94 ng/mL for every 0.1 mg/day increase in folic acid intake in
women aged 20–35 years (14). Wald combined these two results
to predict the reduction in risk resulting from additional folic
acid intake according to background serum folate concentration
(14). This means that the risk reduction in NTD pregnancies
resulting from the adoption of fortification can be predicted if
the prevalence of NTDs in a country and the population serum
folate levels in the country are known.
The aim of this study was to estimate the potential effect
there would have been on the prevalence of NTDs over 20
years from 1998 to 2017 if fortification of flour with folic acid
had been implemented in 1998 in Europe, as was done in the
USA using data from European Congenital Anomaly Registries
on the prevalence of NTDs and data from a literature search
on population serum folate levels. An earlier study quantified
the numbers of pregnancies with an NTD that could have




In 2017 there were 28 countries belonging to the EU, 10 of which
joined in 2004, two in 2007 and one in 2013. When estimating
the numbers of NTDs that could be prevented in Europe from
1998, we have used two groups of countries—the 15 members
in the EU in 1998 (EU15) and the 28 who were members of
the EU in 2019 (EU28). In addition, we provide information
on Norway, Switzerland and Ukraine, who are not members
of the EU, but who have congenital anomaly registries that are
members of EUROCAT (the European network of Congenital
Anomaly Registries).
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Prevalence of Neural Tube Defect
Pregnancies
EUROCAT currently surveys births from 39 registries in 21
countries in Europe (15, 16). The EUROCAT coverage varies over
time according to which registries are able to provide data, with
the maximum coverage being over 1.7 million births per year
(39% of births in Europe). Details on the data and their collection
are available at https://eu-rd-platform.jrc.ec.europa.eu/eurocat_
en. Registries use multiple sources of information to ascertain
cases including maternity, neonatal, and pediatric records; fetal
medicine, cytogenetic, pathology, and medical genetics records;
specialist services including pediatric cardiology; and hospital
discharge and child health records. Anomalies were coded
according to the International Classification of Disease (ICD)
version 10 (17) (ICD-10) or ICD-9 with the British Pediatric
Association (BPA) code extension for higher specificity and
categorized by CA/syndrome subgroup (the system and the
individual disorder), following the EUROCAT guidelines (18).
NTDs include anencephalus, encephalocele and spina bifida.
Cases were coded as having encephalocele only if there was
no mention of anencephalus. Similarly, cases were classified as
having spina bifida only if there was no mention of anencephalus
or encephalocele. All cases with a known genetic condition
were excluded.
Data about cases with an NTD [live births, late fetal
deaths (≥20 weeks’ gestation) and terminations of pregnancy
for fetal anomaly at any gestation (TOPFA)] from 1st
January 1998 to 31st December 2017 were obtained from
the EUROCAT website (https://eu-rd-platform.jrc.ec.europa.eu/
eurocat/eurocat-data/prevalence), as this website allows bespoke
prevalence tables to be obtained interactively. Data were not
available for all countries in Europe and for many countries
the data available only covers births in particular regions and
particular years (see Table 1). EUROCAT collects individual case
data from full member registries, but only aggregate data from
associate registries. Data from associate registries were only used
if data were not available from a full registry in the same country.
Table 1 shows which registries provided data to EUROCAT. Nine
countries currently in the EU do not have any congenital anomaly
registries that are members of EUROCAT. PubMed was searched
for any additional information on the prevalence of NTDs in
these countries from 1998 to 2017 using the terms “neural tube
defect” and each individual country separately. Two studies were
identified providing the prevalence for the Slovak Republic (20)
and for Slovenia (21). For Luxembourg, the prevalence was
assumed to be the same as that in Switzerland, for Greece and
Cyprus the prevalence was assumed to be the same as that in Italy,
for Estonia the prevalence was assumed to be the same as that in
Finland, for Romania, the prevalence was assumed to be the same
as that in Poland and for Latvia and Lithuania the prevalence
was assumed to be the same as the average prevalence in Poland,
Finland and Sweden.
The annual prevalence of NTD pregnancies was estimated
within each registry over the time period during which the
registry was active. For countries in which there were several
registries, the overall prevalence was estimated by calculating the
total number of cases divided by the population births covered
by the registries for each year. For European countries having
registries located outside the geographical limits of Europe, only
mainland registries were included (for example for France the
registry on Isle de Reunion was not included). Previous studies
have shown that the overall prevalence of NTD pregnancies in
Europe has not significantly changed over this period (12, 22).
Therefore, for years in which there was no registry reporting
the prevalence, the average prevalence over the 3 previous years
(where available) or the following 3 years (where available)
was used.
Population Serum Folate Levels
Any information from studies measuring serum folate levels in
women of childbearing age was searched for in PubMed using
the terms “folate” or “folic acid” and each individual European
country separately. In addition, the above search was repeated
using Google Scholar as this search engine also allows searching
of country of authors. If several studies were available from a
single country the largest study in the most recent years was
used (see Table 2) (23–43). Serum folate has a log Gaussian
distribution and therefore the median or geometric mean and
centile values should be reported. Many studies presented the
arithmetic mean and standard deviation (SD). The correct
median and SD (on a log scale) were estimated by simulating
different log Gaussian distributions and calculating the observed
means and SDs until these calculated means and SDs matched
the published values and then the median and SD (on a log
scale) from the simulated distribution were used instead of the
published values. If only the median was available and not the SD,
themedian SD from all the studies was used. As the same increase
in folic acid will result in a greater risk reduction in women
with lower serum folate compared with women with higher
serum folate levels, we divided the serum folate levels in each
country into quintiles and used the quintile medians to predict
the risk reduction in each quintile of women separately. We then
summed the quintiles to obtain the risk reduction in the whole
population. We compared these estimates to the risk reduction
using just the median folate level of the whole population. To
determine how sensitive our estimates were to the reporting of
serum folate levels in the different countries we also calculated
the median serum folate level across all countries and used that
value as the median serum folate level within each country.
Folic Acid Supplementation
Recent studies have found that the proportion of women taking
folic acid supplements at the correct time for prevention of NTDs
(which is 4 weeks before pregnancy and the first 8 to 12 weeks
of pregnancy) varies from around 10.4% (44, 45) up to 35%
(46). An older meta-analysis of 34 studies found that around
25% of women took folic acid supplements periconceptually
(47). Two estimates of the number of NTDs cases prevented
were calculated; (i) Assuming that 25% of women took folic
acid supplementation at the correct time and (ii) Ignoring any
reductions in risk due to folic acid supplementation.
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TABLE 1 | Number and prevalence of neural tube defect (NTD) pregnancies in EUROCAT registries reported from 1998 to 2017 and the proportion of the population
covered over the whole 20 year period.









Belgium Y Y Antwerp 1998 2016 271 0.73 15
Belgium Y Y Hainaut 1998 2017 194 0.79 10
Denmark Y Y Odense 1998 2015 105 1.14 7
France Y Y Auvergne 2002 2015 170 1.05 1
France Y Y Brittany 2011 2017 321 1.31 2
France Y Y Paris 1998 2017 634 1.13 3
Italy Y Y Emilia Romagna 1998 2017 391 0.57 6
Italy Y Y Tuscany 1998 2017 317 0.56 5
Ireland Y Y Cork and Kerry 1998 2017 210 1.16 14
Ireland Y Y Dublin 1998 2012 255 0.70 28
Ireland Y Y SE Ireland 1998 2016 137 1.05 10
Netherlands Y Y North Netherlands 1998 2017 291 0.81 10
UK Y Y East Midlands and South Yorkshire 1998 2017 1,288 1.13 8
UK Y Y Northern England 2000 2017 775 1.35 4
UK Y Y South West England 2005 2017 717 1.12 4
UK Y Y Thames Valley 1998 2017 448 1.04 3
UK Y Y Wales 1998 2017 942 1.41 4
UK Y Y Wessex 1998 2017 684 1.20 4
Portugal Y Y S. Portugal 1998 2017 156 0.43 18
Spain‡ Y Y Basque 1998 2016 374 1.02 4
Spain‡ Y Y Valencian Region 2007 2016 293 0.60 6
Germany Y Y Mainz 1998 2014 89 1.63 0
Germany Y Y Saxony-Anhalt 1998 2017 308 0.92 2
Austria Y Y Styria 1998 2014 129 0.73 11
Finland Y Y Finland (A) 1998 2014 899 0.91 86
Sweden Y Y Sweden (A) 2007 2016 803 0.73 53
Croatia Y N Zagreb 1998 2017 60 0.49 15
Malta Y N Malta 1998 2016 73 0.92 96
Poland Y N Wielkopolska 1999 2017 517 0.73 9
Bulgaria Y N Sofia (A) 1998 1999 40 2.07 1
Hungary Y N Hungary (A) 1998 2012 953 0.66 76
Czech Rep Y N Czech Republic (A) 2000 2010 848 0.74 55
Switzerland N N Vaud 1998 2017 135 0.87 10
Norway N N Norway 1999 2016 907 0.84 92
Ukraine N N Ukraine 2005 2016 650 1.80 4
(A) Associate registry.
*Includes NTDs occurring in live births, fetal deaths (stillbirths and later miscarriages ≥ 20 gestational age) and terminations of pregnancy for fetal anomaly excluding cases with known
genetic conditions.
†
This figure is the total number of births covered by the registry in the years reported divided by the total numbers of births occurring in the countries over the whole 20-year period.
‡The prevalence is confirmed by the data from hospitals recording terminations of pregnancy for fetal anomalies in the Spanish Collaborative Study of Congenital Malformations
(ECEMC)—an associate registry in EUROCAT which covers 16% of all births and includes hospitals from Valencian and Basque regions (19).
Calculation of Number of Neural Tube
Defects Prevented
In the USA, mandatory fortification with 140 µg of folic acid
per 100 g of enriched cereal grain product was fully implemented
in 1998 and has been estimated to provide 200 µg of folic
acid per day to women of childbearing age (48). Wald et al.
estimated that an increase in folic acid intake of 200 µg per
day would increase the average serum folate concentration by
1.88 ng/ml or 4.26 nmol/L in women of childbearing age (14).
We therefore estimated that the average serum folate level would
have increased by 4.26 nmol/L in each country if fortification had
occurred. The predicted reduction in prevalence if fortification
had occurred is given by the formula: reduction in prevalence
= (new serum folate/original serum folate)−0.81 from Wald et
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TABLE 2 | Estimated median folate levels and standard deviations (on a log scale) in European countries.








Austria Y Y 11.5 0.77 (23)
Belgium Y Y 13.8 0.41 (24)
Denmark Y Y 8.6 0.29 (25)
Finland Y Y 12.4 0.55 (26)
France Y Y 14.8 0.58 (27)
Germany Y Y 14.3 0.41 (28)
Greece Y Y 17.4 0.69 (29)
Ireland Y Y 16.2 0.53 (30)
Italy Y Y 10.4 0.45 (31)
Luxembourg Y Y Values from Switzerland used
Netherlands Y Y 7.3 0.48 (32, 33)
Portugal Y Y 15.2 0.42 (34)
Spain Y Y 16.5 0.51 (35)
Sweden Y Y 15.0 0.40 (36)
United Kingdom Y Y 16.2 0.54 (30)
Bulgaria Y N Values from Poland used
Croatia Y N 9.1 (37)
Cyprus Y N Values from Greece used
Czech Republic Y N 14.0 0.38 (38)
Estonia Y N 12.4 0.60 (39)
Hungary Y N 19.0 0.45 (38)
Latvia Y N Values from Poland used
Lithuania Y N Values from Poland used
Malta Y N Values from Greece used
Poland Y N 14.3 0.52 (40)
Romania Y N Values from Poland used
Slovak Republic Y N 16.0 0.35 (41)
Slovenia Y N Values from Poland used
Norway N N 7.3 0.50 (42)
Switzerland N N 14.3 0.67 (43)
Ukraine N N [3.2] Values estimated from prevalence of NTDs
Estimated median in countries in EU in 1998 14.1 Median weighted by numbers of births in each population.
Estimated median in countries in EU in 2019 14.1 Median weighted by numbers of births in each population.
al. (14). For the scenario of 25% of women taking folic acid
supplements, the effect of fortification is assumed to apply to only
75% of all births.
The total number of NTD diagnoses prevented from
occurring annually in each country was estimated by multiplying
the reduction in prevalence in the country by the total
number of births in the country in that year. The numbers of
births were obtained from Eurostat if they were not available
from the EUROCAT registries (https://ec.europa.eu/eurostat/
databrowser/view/TPS00204/default/table).
Patient and Public Involvement
This study was not funded and therefore there were no funds or
time allocated for PPI so we were unable to involve patients. We
will invite patients to help us develop our dissemination strategy.
RESULTS
From 1998 to 2017 an estimated 95,213 NTD pregnancies
occurred amongst 104 million births in the 28 countries in the
EU in 2019, a prevalence of 0.92 per 1,000 births. The median
serum folate level in Europe over this time period was estimated
to be 14.1 nmol/L.
Table 3 shows that 14,600 NTD pregnancies could have been
averted if the 28 countries in the EU in 2019 had implemented
fortification at the level adopted by the USA in 1998, assuming
that at least 25% of women in these countries had taken folic
acid supplements before becoming pregnant and would therefore
not have received a benefit from fortification. An estimated
19,500 NTD pregnancies could have been averted if it is assumed
that no supplementation is occurring as then all women in
the population are assumed to benefit from fortification. As it
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TABLE 3 | NTD: numbers of pregnancies and the prevalence if fortification had occurred from 1998 to 2017 according to European country.
Country EU member Assuming no supplementation occurred Assuming 25% of women took supplements (47)





















Austria Y Y 0.71 0.53 25 279 0.57 19 209
Belgium Y Y 0.75 0.60 20 369 0.63 15 276
Denmark Y Y 1.12 0.80 28 394 0.88 21 296
Finland Y Y 0.90 0.70 23 234 0.75 17 175
France Y Y 1.16 0.93 20 3,735 0.99 15 2,801
Germany Y Y 1.02 0.82 20 2,893 0.87 15 2,170
Greeceb Y Y 0.57 0.46 18 214 0.49 14 160
Ireland Y Y 0.93 0.75 18 222 0.80 14 166
Italy Y Y 0.57 0.43 25 1,526 0.46 19 1,145
Luxembourga Y Y 0.87 0.70 20 20 0.74 15 15
Netherlands Y Y 0.82 0.55 32 962 0.62 24 721
Portugal Y Y 0.43 0.35 19 168 0.37 14 126
Spain Y Y 0.85 0.69 18 1,332 0.73 14 999
Sweden Y Y 0.79 0.64 19 315 0.67 14 237
United Kingdom Y Y 1.22 0.99 18 3,344 1.05 14 2,508
Bulgaria Y N 1.63 1.26 22 510 1.35 17 382
Croatia Y N 0.49 0.36 28 112 0.39 21 84
Cyprusb Y N 0.57 0.47 17 25 0.49 13 18
Czech Republic Y N 0.73 0.59 20 306 0.62 15 230
Estoniac Y N 0.90 0.70 23 58 0.75 17 43
Hungary Y N 0.64 0.54 16 193 0.56 12 145
Latviad Y N 0.82 0.64 22 77 0.68 17 58
Lithuaniad Y N 0.82 0.64 22 115 0.69 17 86
Malta Y N 0.92 0.76 17 13 0.80 13 10
Poland Y N 0.77 0.61 20 1,173 0.65 15 879
Romaniae Y N 0.77 0.61 22 746 0.65 17 559
Slovak Republicf Y N 0.53 0.43 18 106 0.46 13 80
Sloveniag Y N 0.74 0.57 22 65 0.62 17 49
Norway N N 0.84 0.57 32 312 0.63 24 234
Switzerland N N 0.87 0.69 21 286 0.73 16 214
Ukraine N N 1.80 0.91 49 8,047 1.13 37 6,035
Countries in EU in 1998 0.95 21 16,007 15 12,005
Countries in EU in 2019 0.92 21 19,504 15 14,628
aFor Luxembourg the prevalence was assumed to be the same as that in Switzerland.
bFor Greece and Cyprus the prevalence was assumed to be the same as that in Italy.
cFor Estonia the prevalence was assumed to be the same as that in Finland.
dFor Latvia and Lithuania the prevalence was assumed to be the same as the mean of Poland, Finland and Sweden.
eFor Romania the prevalence was assumed to be the same as that in Poland.
fPrevalence in Slovak Republic from Behunova et al. (20).
gPrevalence in Slovenia from Kokalj et al. (21).
†
The prevalence may differ slightly from that in Table 1 as in Table 3 it is the prevalence over the whole time period from 1998 to 2017 and in Table 1 it is the prevalence for the years
of available data.
is likely that fewer than 25% of women in Europe did take
supplements at the correct time and also that these women
would have received some benefit from fortification the true
estimate of the number of NTDs prevented lies between 14,600
and 19,500; a 15–21% reduction. This is equivalent to saying
fortification could prevent almost 1,000 pregnancies with an
NTD occurring every year in the 28 countries in the EU.
If only those countries in the EU in 1998 had implemented
fortification then the number of NTD pregnancies that would
have been prevented lies between 12,000 and 16,000 (again 15%
to 21% reduction).
The two different methods of estimating the effect of
fortification used (that is using the median value or splitting
the distribution into quintiles) gave similar answers to the
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nearest percentage point reduction in prevalence and therefore
for simplicity the median method was used. Assuming that all
countries had the same medium serum folate level (of 14.1
nmol/L) resulted in the reductions in NTD pregnancies being
15 and 20% (with and without supplementation, respectively).
This would be expected as if the serum folate is assumed
to be 10 nmol/L for example the predicted reduction in
NTD pregnancies will be large, but if it is assumed to be
14.1 nmol/L the predicted reduction will be smaller. In other
words, all those countries with serum folate below the median
will have smaller reductions predicted if it is assumed their
serum folate is the level of the median value. Similarly all
those countries with serum folate levels above the median
will have greater reductions predicted if it is assumed their
serum folate is the level of the median. These effects are likely
to be of a similar magnitude and hence the overall estimate
remains similar.
DISCUSSION
This study suggests that failure to implement folic acid
fortification has resulted in an estimated 15,000–20,000
pregnancies affected with an NTD in the EU from 1998 to
2017. In Chile, the level of flour fortification adopted was higher
than that in the USA (2.2 µg/100 g flour vs. 1.4 µg/100 g).
If this level of fortification had been adopted in the EU, the
reduction in affected pregnancies would have been twice as
large. Given the known benefits, there is no reason not to adopt
the level of fortification introduced in Chile in all countries
in the EU.
This paper has used robust methods to estimate the numbers
of NTD-affected pregnancies that could have been prevented by
fortification. The method was compared to an earlier study in the
UK, which predicted that 2014 affected pregnancies could have
been prevented in the UK from 1998 to 2012 (49). This compares
with 2,508 in this study from 1998 to 2017 (given in Table 3)
which is consistent with the earlier study.
A weakness of the study is that there is very little information
on population serum folate levels in all the countries across
the 20-year study period. Measurements of serum folate in
women of childbearing age were obtained for 21 countries,
but assumptions about serum folate needed to be made for
the other countries (see Table 2). In addition, most serum
folate values related to one point in time only and often
from only a small sample of people as in Portugal with
data only from a small sample of women and men. For
Ukraine (not included in the European estimates but included
in the study for completeness), there were no population
estimates of serum folate. The prevalence of NTD pregnancies
in Ukraine is extremely high and therefore this prevalence
was used to estimate the serum folate levels—they would be
expected to be considerably lower than any other European
country. Serum folate levels were often analyzed in papers
assuming serum folate had a Gaussian distribution, which
is not a correct assumption and the median and SD (on
a log scale) had to be estimated. However, the sensitivity
analysis did demonstrate that assuming the folate levels were
the same in all countries decreased the estimated numbers of
NTDs prevented by only 1%, demonstrating the robustness of
the estimation.
A further weakness in this study is that as there were no
known NTD prevalence figures for several European countries,
with assumptions needing to be made. These assumptions
may not be correct. In addition, full member registries in
EUROCAT submit individual case data which are extensively
analyzed to ensure consistent coding within all EUROCAT
registries. Associate member registries only submit aggregate
data which limits the amount of data quality checks that
can be performed on them. Even in those countries with
EUROCAT registries, the registries may only cover a small
proportion of all births in a country requiring generalization
about the whole population to be made. For Spain the prevalence
was obtained from two full member registries and confirmed
by the prevalence in the associate registry—The Spanish
Collaborative Study of Congenital Malformations (ECEMC)
which has a greater coverage of 16% of births over the same time
period (19).
Information on whether the mothers who had had an
affected pregnancy took folic acid supplements before and
during the first trimester of pregnancy would have been
very informative, but unfortunately information on folic
acid consumption is not well recorded in the EUROCAT
registries, partly because such supplements are available
as over the counter medications and do not require
a prescription.
In many European countries preconceptual folic acid
supplementation is not covered by the national health systems,
which means that this important preventive measure is subject
to individual’s being able to afford it, which increases inequity
in society.
The main obstacle for folic acid fortification was the concern
that it may result in a proportion of the population consuming
too much folate. In 2000, the European Commission Scientific
Committee on Food report stated that “Although there is no
conclusive evidence in humans, the Committee concludes that
the risk of progression of the neurological symptoms in vitamin
B12 deficient patients as a result of folic acid supplementation
cannot be excluded and should be considered the most serious
adverse effect” (50). However, a recent paper demonstrated
that the evidence used by the Food and Nutrition Board at the
Institute of Medicine (IOM) of the National Academies (formerly
National Academy of Sciences) in the USA to develop the Dietary
Reference Intake for folate was scientifically flawed and that
there is no level of folate which increases the risk of progression
of the neurological symptoms in vitamin B12 deficient
patients (3).
This study suggests that the lack of adoption of an
extremely cheap and effective intervention will continue to
result in an estimated additional 1,000 affected pregnancies
each year. We therefore suggest that all flour and other
non-wheat products such as “gluten free” be fortified in the
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European countries with at least 2.2 µg Folic acid/100 g flour
or equivalent.
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